Abstract Number: 2606 • ACR Convergence 2024
Changes in Long-term GC Use Among Older Adults After New Diagnosis of Late-onset Rheumatoid Arthritis
Background/Purpose: Older adults with late-onset rheumatoid arthritis (LORA) receive less disease-modifying anti-rheumatic drugs (DMARDs), which is the standard of care. In contrast, long-term glucocorticoid (GC)…Abstract Number: 2609 • ACR Convergence 2024
Drivers of Infliximab Biosimilar Uptake: A Comparative Analysis of New Biosimilar Initiations versus Switching in a National Rheumatology Registry
Background/Purpose: Biosimilars hold promise for reducing pharmaceutical expenditures, however uptake has lagged. We analyzed the variability in new biosimilar starts and switching from bio-originator infliximab…Abstract Number: 0141 • ACR Convergence 2023
In-patient Outcome Difference in Systemic Lupus Erythematous Patient Between Medicare and Non-Medicare Group, a Nationwide Analysis
Background/Purpose: Systemic lupus erythematosus is a chronic inflammatory disorder that significantly burdens our health system. The study aimed to understand the difference in in-patient outcomes…Abstract Number: 0181 • ACR Convergence 2023
Increased Prevalence of and Acute Hospital Events Among Medicare Systemic Lupus Erythematosus Patients Living in Socially Vulnerable Counties in the United States
Background/Purpose: Systemic Lupus Erythematosus (SLE) is more prevalent and has greater adverse health outcomes in women, minorities, and individuals with low socioeconomic status (SES), particularly…Abstract Number: 0457 • ACR Convergence 2023
Biologic Disease Modifying Antirheumatic Drug Use in Immune Checkpoint Inhibitor-Treated Cancer Patients with Rheumatoid Arthritis: Utilization and Overall Survival
Background/Purpose: There is a dearth of knowledge around the safety of biologic disease modifying antirheumatic drugs (bDMARDS) in immune checkpoint inhibitor (ICI)-treated rheumatoid arthritis (RA)…Abstract Number: 0967 • ACR Convergence 2023
Overall Survival in Patients with versus Without Rheumatoid Arthritis Initiating Immune Checkpoint Inhibitors for Metastatic Non Small Cell Lung Cancer
Background/Purpose: Immune checkpoint inhibitors (ICI) increase one-year survival in metastatic non-small cell lung cancer (mNSCLC) from 49% to 69% with chemotherapy-based regimens. Patients with rheumatoid…Abstract Number: 1615 • ACR Convergence 2023
Therapeutic Hydroxychloroquine Blood Levels Are Cost Effective and May Reduce Health Disparities by Reducing Lupus Hospitalizations
Background/Purpose: Studies show factors including daily hydroxychloroquine (HCQ) dosing or nonadherence affect blood concentrations risking 6-fold higher lupus (or SLE) flares requiring hospitalization. Given disparities…Abstract Number: 1619 • ACR Convergence 2023
Receipt of Antimicrobial Prophylaxis in U.S. Medicare Beneficiaries Initiating Immunosuppressive Medications for ANCA Vasculitis
Background/Purpose: Infections are the leading cause of hospitalization and mortality in patients with ANCA vasculitis (AV). Multiple AV treatment guidelines recommend antimicrobial prophylaxis during treatment…Abstract Number: 1799 • ACR Convergence 2023
Association of Pregabalin vs Gabapentin with Incident Congestive Heart Failure in Patients with Non-Cancer Pain
Background/Purpose: Chronic pain affects 30% of all patients in developed countries, accounting for up to 35% of prescriptions in acute care settings. Non-opioid pain medications…Abstract Number: 1850 • ACR Convergence 2023
Long-term Glucocorticoid Use in a Cohort of Elderly Early Rheumatoid Arthritis Patients: A Joint Analysis of Medicare and the Rheumatology Informatics System for Effectiveness (RISE) Data
Background/Purpose: According to recent ACR and EULAR rheumatoid arthritis (RA) guidelines, glucocorticoids (GCs) should only be used for brief periods or not at all. Our…Abstract Number: 2528 • ACR Convergence 2023
Current Trends in the Risk of Subsequent Fracture After Initial Fracture, and Post-Fracture Treatment Among Commercially Insured Postmenopausal Women in the United States
Background/Purpose: Recent studies suggest that post-fracture pharmacologic management has been declining in the U.S. despite an increase in the burden of osteoporosis (OP). In light…Abstract Number: 0071 • ACR Convergence 2022
Workforce Changes and Characteristics of Adult Rheumatologists in a United States Medicare Claims Analysis
Background/Purpose: Prior studies have projected inadequate growth in the rheumatology provider workforce to keep up with population demand. The objective of this project was to…Abstract Number: 0707 • ACR Convergence 2022
Accuracy of Administrative Claims Prescription Fill Data to Estimate Glucocorticoid Use and Dose in Patients with Rheumatoid Arthritis
Background/Purpose: Glucocorticoids (GCs) are used commonly to treat patients with rheumatoid arthritis (RA) and other inflammatory conditions. As clinical trials are often underpowered to assess…Abstract Number: 1195 • ACR Convergence 2022
Duloxetine and the Risk for Acute Myocardial Infarction and Stroke in Medicare Recipients with Non-Cancer Pain
Background/Purpose: Duloxetine is a serotonin-norepinephrine reuptake inhibitor antidepressant also prescribed for musculoskeletal and other forms of chronic pain. Its dual pharmacologic properties have the potential…Abstract Number: 2200 • ACR Convergence 2022
Reliability of Medication Information Derived from EHR Data Compared to Insurance Claims: An Analysis of Biologic Medications in RISE and Medicare
Background/Purpose: Health services studies increasingly rely on Electronic Health Record (EHR) data to capture medication use. However, the reliability of medication information derived from EHR…
ACR Meeting Abstracts